Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.38 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.38 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657700 | 0.85 | ENPP2 (0.39) | ENPP2ORAI1ORAI2ORAI3IKBKB | |
| SCHEMBL29956241 | 0.81 | ENPP2 (0.39) | ENPP2ORAI1ORAI2ORAI3IKBKB | |
| SCHEMBL5039573 | 0.81 | ENPP2 (0.39) | ENPP2ORAI1ORAI2ORAI3IKBKB | |
| SCHEMBL29953746 | 0.79 | ENPP2 (0.38) | ENPP2ORAI1ORAI2ORAI3IKBKB | |
| SCHEMBL31016790 | 0.79 | ENPP2 (0.38) | ENPP2ORAI1ORAI2ORAI3IKBKB | |
| SCHEMBL16110848 | 0.75 | CCR1 (0.38) | CA2 | |
| SCHEMBL29954504 | 0.75 | CCR1 (0.38) | CA2 | |
| SCHEMBL29864602 | 0.74 | GRM1 (0.34) | ENPP2ORAI1ORAI2ORAI3IKBKB | |
| SCHEMBL8198856 | 0.74 | KDM4E (0.45) | MAOAPDE2APDE4APDE4BPDE4C | |
| SCHEMBL176249 | 0.73 | ALDH1A1 (0.47) | ENPP2ORAI1ORAI2ORAI3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| EP-1569911-B1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-02 | — | — | EP | disclosed |
| US-20070213373-A1 | Indazole derivatives as CRF antagonists | COURNOYER RICHARD L | 2007-09-13 | — | — | US | disclosed |
| US-7214699-B2 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1569911-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050634-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | SCN1A, SCN1B, SCN5A | ENPP2 317/4885ORAI1 219/4885ORAI2 166/4885 |
| US-20070213373-A1 | Indazole derivatives as CRF antagonists | CRHR1, CRHR2, CRH | ENPP2 2032/4885ORAI1 2711/4885ORAI2 2099/4885 |
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | CRHR1, CRHR2, ARRB1 | ENPP2 2036/4885ORAI1 2979/4885ORAI2 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.